BAYER AG ORD (OTCMKTS:BAYZF) Could Burn Your Long Portfolio After More Shorts

December 8, 2017 - By Marie Mckinney

The stock of BAYER AG ORD (OTCMKTS:BAYZF) registered an increase of 6.57% in short interest. BAYZF’s total short interest was 929,500 shares in December as published by FINRA. Its up 6.57% from 872,200 shares, reported previously. With 2,200 shares average volume, it will take short sellers 423 days to cover their BAYZF’s short positions.

The stock increased 0.40% or $0.4875 during the last trading session, reaching $122.3875. About shares traded. Bayer Aktiengesellschaft (OTCMKTS:BAYZF) has 0.00% since December 8, 2016 and is . It has underperformed by 16.70% the S&P500.

Bayer Aktiengesellschaft operates as a life science firm worldwide. The company has market cap of $101.84 billion. The firm operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro divisions. It has a 11.67 P/E ratio. The Pharmaceuticals segment offers prescription products primarily for cardiology and womenÂ’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

More notable recent Bayer Aktiengesellschaft (OTCMKTS:BAYZF) news were published by: Insurancejournal.com which released: “Jury Says J&J, Bayer Must Pay $28 Million for Woman’s Injuries from Xarelto Drug” on December 07, 2017, also Bostonglobe.com with their article: “J&J, Bayer ordered to pay $28 million in first Xarelto loss” published on December 06, 2017, Seekingalpha.com published: “Antitrust reviews going into ‘unimaginable depths,’ Bayer CEO says” on November 29, 2017. More interesting news about Bayer Aktiengesellschaft (OTCMKTS:BAYZF) were released by: Reuters.com and their article: “CFIUS clears Bayer’s planned takeover of Monsanto” published on December 01, 2017 as well as Reuters.com‘s news article titled: “Bayer says antitrust reviews going into ‘unimaginable depths'” with publication date: November 29, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: